Investors often chase “story stocks” without profits, but seasoned investors recognize the value of profitability, as evidenced by firms like Vytrus Biotech (BME:VYT). Vytrus has demonstrated impressive growth, increasing its earnings per share (EPS) from €0.14 to €0.39 in just one year—a staggering 184% rise. Additionally, their EBIT margins increased from 16% to 33% alongside revenue growth, suggesting a sustainable competitive advantage. With insiders holding 34% of the company, their investment fosters confidence in management’s decisions. Despite this optimism, potential investors should be cautious of two warning signs in the company’s analysis.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/es/household/bme-vyt/vytrus-biotech-shares/news/if-eps-growth-is-important-to-you-vytrus-biotech-bmevyt-pres
